Skip to main content
Top
Published in: BMC Neurology 1/2022

Open Access 01-12-2022 | Lymphopenia | Case report

Progressive multifocal leukoencephalopathy in a patient with mediastinal teratoma: a case report

Authors: Wei Wang, Hui Yang, Yueshan Piao, Meina Quan, Dongmei Guo

Published in: BMC Neurology | Issue 1/2022

Login to get access

Abstract

Background

Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating lytic brain infection caused by the John Cunningham virus (JCV). JCV manifests primarily in patients with innate immunodeficiency or taking immunomodulatory medications. In this case study, we report a PML patient with comorbid mediastinal teratoma and mild lymphopenia.

Case presentation

A 73-year-old female presented with a 3-month history of progressive hemiplegia, hemianopsia, and cognitive impairment. She was diagnosed as PML by cerebrospinal fluid metagenomics sequencing and brain biopsy. Extensive immunological tests did not reveal an apparent immunodeficiency, but further work-up revealed that the PML was most likely the first presentation of mediastinal teratoma and the mild lymphopenia. Mirtazapine and immunoglobulin were started, the patient’s condition was relatively stable and approved to be discharged from hospital. But unfortunately, she died of the lung infection 10 months after first presentation.

Conclusions

This case confirms that mediastinal teratoma may induce the lymphopenia and trigger PML, delayed or incorrect diagnosis may worsen the course of the disease and result in poor prognosis.
Literature
1.
go back to reference Ferenczy MW, Marshall LJ, Nelson CD, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 2012;25:471–506.CrossRef Ferenczy MW, Marshall LJ, Nelson CD, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 2012;25:471–506.CrossRef
2.
go back to reference Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, et al. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume with JC virus polymerase chain reaction results in cerebrospinal fluid of Natalizumab-treated patients with multiple sclerosis. JAMA Neurol. 2018;75:827–33.CrossRef Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, et al. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume with JC virus polymerase chain reaction results in cerebrospinal fluid of Natalizumab-treated patients with multiple sclerosis. JAMA Neurol. 2018;75:827–33.CrossRef
3.
go back to reference Beltrami S, Gordon J. Immune surveillance and response to JC virus infection and PML. J Neuro-Oncol. 2014;20:137–49. Beltrami S, Gordon J. Immune surveillance and response to JC virus infection and PML. J Neuro-Oncol. 2014;20:137–49.
4.
go back to reference Sriwastava S, Kataria S, Srivastava S, et al. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: a systematic review and meta-analysis. J Neuroimmunol. 2021;360:577721.CrossRef Sriwastava S, Kataria S, Srivastava S, et al. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: a systematic review and meta-analysis. J Neuroimmunol. 2021;360:577721.CrossRef
5.
go back to reference D'Amico E, Zanghi A, Leone C, Tumani H, Patti F. Treatment-related progressive multifocal leukoencephalopathy in multiple sclerosis: a comprehensive review of current evidence and future needs. Drug Saf. 2016;39:1163–74.CrossRef D'Amico E, Zanghi A, Leone C, Tumani H, Patti F. Treatment-related progressive multifocal leukoencephalopathy in multiple sclerosis: a comprehensive review of current evidence and future needs. Drug Saf. 2016;39:1163–74.CrossRef
6.
go back to reference Gofton TE, Al-Khotani A, O'Farrell B, Ang LC, McLachlan RS. Mefloquine in the treatment of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry. 2011;82:452–5.CrossRef Gofton TE, Al-Khotani A, O'Farrell B, Ang LC, McLachlan RS. Mefloquine in the treatment of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry. 2011;82:452–5.CrossRef
7.
go back to reference Chabwine JN, Lhermitte B, Da Silva MO, Buss G, Maeder P, Du Pasquier RA. Progressive multifocal leukoencephalopathy in a patient with transitory lymphopenia. Neurology. 2012;78:2000–2.CrossRef Chabwine JN, Lhermitte B, Da Silva MO, Buss G, Maeder P, Du Pasquier RA. Progressive multifocal leukoencephalopathy in a patient with transitory lymphopenia. Neurology. 2012;78:2000–2.CrossRef
8.
go back to reference Gamperl I, Enzinger C, Pichler A, Feichtinger M, Schlager T, Fertl E. Can pulmonary sarcoidosis trigger a progressive multifocal leukoencephalopathy? Considerations from a case series and a review of literature. Clin Case Rep. 2018;6:2121–5.CrossRef Gamperl I, Enzinger C, Pichler A, Feichtinger M, Schlager T, Fertl E. Can pulmonary sarcoidosis trigger a progressive multifocal leukoencephalopathy? Considerations from a case series and a review of literature. Clin Case Rep. 2018;6:2121–5.CrossRef
9.
go back to reference Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious disease section. Neurology. 2013;80:1430–8.CrossRef Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious disease section. Neurology. 2013;80:1430–8.CrossRef
10.
go back to reference Kinsella S, Dudakov JA. When the damage is done: injury and repair in Thymus function. Front Immunol. 2020;11:1745.CrossRef Kinsella S, Dudakov JA. When the damage is done: injury and repair in Thymus function. Front Immunol. 2020;11:1745.CrossRef
11.
go back to reference Legrand N, Dontje W, van Lent AU, Spits H, Blom B. Human thymus regeneration and T cell reconstitution. Semin Immunol. 2007;19:280–8.CrossRef Legrand N, Dontje W, van Lent AU, Spits H, Blom B. Human thymus regeneration and T cell reconstitution. Semin Immunol. 2007;19:280–8.CrossRef
12.
go back to reference Fink PJ, Hendricks DW. Post-thymic maturation: young T cells assert their individuality. Nat Rev Immunol. 2011;11:544–9.CrossRef Fink PJ, Hendricks DW. Post-thymic maturation: young T cells assert their individuality. Nat Rev Immunol. 2011;11:544–9.CrossRef
13.
go back to reference Dixit VD. Impact of immune-metabolic interactions on age-related thymic demise and T cell senescence. Semin Immunol. 2012;24:321–30.CrossRef Dixit VD. Impact of immune-metabolic interactions on age-related thymic demise and T cell senescence. Semin Immunol. 2012;24:321–30.CrossRef
14.
go back to reference Toorop AA, van Lierop ZYG, Strijbis EEM, et al. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. Neurol Neuroimmunol Neuroinflamm. 2020;13;8:e904. Toorop AA, van Lierop ZYG, Strijbis EEM, et al. Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. Neurol Neuroimmunol Neuroinflamm. 2020;13;8:e904.
Metadata
Title
Progressive multifocal leukoencephalopathy in a patient with mediastinal teratoma: a case report
Authors
Wei Wang
Hui Yang
Yueshan Piao
Meina Quan
Dongmei Guo
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2022
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-022-02563-y

Other articles of this Issue 1/2022

BMC Neurology 1/2022 Go to the issue